What is Thyreos?
Thyreos is dedicated to developing advanced prophylactic vaccines for neuroinvasive herpesvirus infections. Leveraging a proprietary recombinant herpesvirus platform, the company's technology is engineered to elicit robust immune responses without causing infection of the nervous system. This dual-market approach targets critical needs in both veterinary and human healthcare, positioning Thyreos as a key player in the infectious disease vaccine sector. The company's focus on neuroinvasive herpesviruses addresses a significant unmet medical need across species.
How much funding has Thyreos raised?
Thyreos has raised a total of $2.6M across 2 funding rounds:
Other Financing Round
$1M
Grant
$1.6M
Other Financing Round (2023): $1M, investors not publicly disclosed
Grant (2023): $1.6M led by National Institute of Allergy and Infectious Diseases
Key Investors in Thyreos
National Institute of Allergy and Infectious Diseases
The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, focuses on discovering and developing vaccines and antibody-based products for infectious diseases, including research into vaccines for various viruses.
What's next for Thyreos?
With the recent infusion of capital, Thyreos is poised to accelerate its research and development pipeline, potentially advancing its herpesvirus vaccine candidates toward clinical trials and market entry. The strategic nature of the latest investment suggests a focus on scaling operations, expanding its scientific team, and forging key partnerships within the animal health and human pharmaceutical industries. This funding will be instrumental in validating the efficacy and safety of their platform, paving the way for broader application in preventing debilitating herpesvirus infections.
See full Thyreos company page
